NOACs have a different mechanism of action and do not require frequent monitoring or dose adjustments that warfarin does.
Significantly, NOACs were priced substantially higher than existing therapies – approximately 20 times more expensive.
This period includes the final nine months before NOACs began entering the market.
Over the five-year study period, NOACs became more popular than warfarin, particularly among younger adults.
Indeed, health plans paid a disproportionately large share of the additional expense for NOACs.
Virginia Voters Are Concerned About Drug Affordability
Prescription drug affordability is a concern for many Virginia voters.
They call for a Prescription Drug Affordability Board to address the issue.
